Notice regarding Conversion of Financial Products
NZX Code: ATM
ASX Code: A2M
8 March 2021
NZX/ASX Market Release
Notice regarding Conversion of Financial Products
For the purposes of NZX Listing Rule 3.15.2 and ASX Listing Rule 3.10.7, The a2 Milk Company (NZX: ATM, ASX: A2M)
provides notice that the following securities have become convertible into fully paid ordinary shares (Ordinary
Shares) in connection with its Long Term Incentive Plan (LTI Plan), and have been converted, as set out below.
No new ordinary shares have been issued in connection with the conversion.
(a) Number of Financial Products converted
and the number and Class of Quoted
Financial Products into which they have
been converted:
297,300 performance rights (granted under the Company’s
FY18 LTI Plan) converted into 297,300 Ordinary Shares,
resulting in 266,545 Ordinary Shares being transferred from the
a2MC Group Employee Share Trust (Share Trust) to FY18 LTI
Plan participants, and 30,755 Ordinary Shares being withheld
by the trustee of the Share Trust (Trustee) to satisfy the
Company’s withholding tax obligations for U.S. based LTI Plan
participants. The Ordinary Shares were acquired on-market by
the Trustee for this purpose.
(b) Event giving rise to the right of
conversion:
Issue of vesting notifications from the Board following
satisfaction of vesting conditions that include performance
hurdles.
(c) Details of any interest or dividend
conditions attaching to the Financial
Products into which they have been
converted:
None
(d) Number of Financial Products of the
same Class remaining to be converted:
820,535 performance rights
(e) Conversion period: From 8 March 2021 to 8 June 2021
(f) Date of conversion: 8 March 2021
The a2 Milk Company Limited
Authorised by Jaron McVicar,
General Counsel and Company Secretary
For further information, please contact:
David Akers
Head of Investor Relations
T +61 2 9697 7013 l M +61 412 944 577
david.akers@a2milk.com
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: Capital Change Notice – Issue of ordinary shares2021-04-13
“Capital Change Notice AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 14 April 2021 Issue of ordinary shares This notice is given u…”
- AFT — AFT Pharmaceuticals Limited: Capital Change Notice – Issue of ordinary shares2021-05-03
“Capital Change Notice AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com 3 May 2021 Issue of ordinary shares This notice is given under…”
- NZX — NZX Limited: Issue of ordinary shares and performance rights2021-03-14
“NZX Limited Level 1, NZX Centre 11 Cable Street PO Box 2959 Wellington 6140 New Zealand Tel +64 4 472 7599 www.nzx.com Page 1 of 2 15 March 2021 Notice of issue and lapsing of performance rights to employees of NZX Limited (NZX) This notice is given under NZX Li…”